Status:
COMPLETED
Patent Foramen Ovale Closure in Migraine
Lead Sponsor:
Haiyan Wang
Conditions:
Migraine
Patent Foramen Ovale
Eligibility:
All Genders
Brief Summary
The goal of this observational study is to retrospectively observe the effect of PFO closure and medication on migraine. The main questions it aims to answer are: * Whether PFO closure is more effect...
Detailed Description
Migraine patients with PFO who were admitted to our hospital from January 2018 to August 2021 were enrolled.They will be treated with medication and PFO closure respectively according to guidelines. H...
Eligibility Criteria
Inclusion
- Closure group:
- Migraine patients with grade II-III RLS of PFO confirmed by cTTE.
- HIT-6≥50.
- Meeting the surgical indications of PFO closure according to Chinese expert consensus on Prophylactic Closure of Patent foramen ovale published in March 2017
- Patients who have underwent PFO closure.
- Drug group:
- Migraine patients with grade II-III RLS of PFO confirmed by cTTE.
- HIT-6 ≥ 50.
- Patients who have underwent drug treatment for 12 months.
Exclusion
- Congenital heart diseases, cardiomyopathy, heart failure, valvular heart disease, arrhythmia, severe hypertension or other heart diseases.
- Patients with serious complications after closure.
- Patients who have other known triggers of migraine.
- Patients with incomplete follow-up data.
Key Trial Info
Start Date :
September 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 20 2023
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT06192173
Start Date
September 5 2022
End Date
May 20 2023
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University
Jinan, China, 250000